Document is current
Any future updates will be listed below
-
Authors
Wang, Zhenguang
Li, Na
Feng, Kaichao
Chen, Meixia
Zhang, Yan
Liu, Yang
Yang, Qingming
Nie, Jing
Tang, Na
Zhang, Xingying
Cheng, Chen
Shen, Lianjun
He, Jiaping
Ye, Xun
Cao, Wei
Wang, Haoyi
Han, Weidong http://orcid.org/0000-0003-3207-3899
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (31991171, 81830002, 81773269, 31722036)
National Key Research and Development Program of China
Strategic Priority Research Program of the Chinese Academy of Sciences
- License Information
-
More Information
Article History
Received: 18 May 2021
Accepted: 21 July 2021
First Online: 11 August 2021
Competing interests
: L.J.S., J.P.H., X.Y. and W.C. are employees of Gracell Biotechnologies (Shanghai) Co., Ltd., whose potential product was studied in this work. H.Y.W. was a consultant of Gracell Biotechnologies (Shanghai) Co., Ltd., Institute of Zoology, Chinese Academy of Sciences, and has a technology assignment agreement with Gracell Biotechnologies (Shanghai) Co., Ltd., for CRISPR-Cas9-mediated <i>PDCD1</i> and <i>TRAC</i> gene editing methods in mesothelin-directed CAR-T cells.
